Literature DB >> 20564543

Antiangiogenic phytochemicals and medicinal herbs.

Soo-Jin Jeong1, Wonil Koh, Eun-Ok Lee, Hyo-Jung Lee, Hyo-Jeong Lee, Hyunsu Bae, Junxuan Lü, Sung-Hoon Kim.   

Abstract

Medicinal herbs and their phytochemicals are potential novel leads for developing antiangiogenic drugs. This review aims to assess the current status of research with medicinal herbs and their phytochemicals for the development of antiangiogenic agents for cancer and other angiogenesis-related diseases including inflammation, diabetic retinopathy, endometriosis and obesity. Most studies reviewed have focused on vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor 2 (VEGFR-2) signaling for endothelial response processes and have led to the identification of many potential antiangiogenic agents. Since human clinical trials with antiangiogenic modalities targeting VEGF/VEGFR-2 signaling have shown limited efficacy and occasional toxic side effects, screening strategies for herbal phytochemicals based on other signaling pathways important for cancer-endothelial and stromal crosstalks should be emphasized in the future.
Copyright © 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20564543     DOI: 10.1002/ptr.3224

Source DB:  PubMed          Journal:  Phytother Res        ISSN: 0951-418X            Impact factor:   5.878


  9 in total

1.  Inhibition of Angiogenesis and Nitric Oxide Synthase (NOS), by Embelin & Vilangin Using in vitro, in vivo & in Silico Studies.

Authors:  Radhakrishnan Narayanaswamy; Majumder Shymatak; Suvro Chatterjee; Lam Kok Wai; Gnanamani Arumugam
Journal:  Adv Pharm Bull       Date:  2014-12-31

Review 2.  Plants vs. cancer: a review on natural phytochemicals in preventing and treating cancers and their druggability.

Authors:  Hu Wang; Tin Oo Khor; Limin Shu; Zheng-Yuan Su; Francisco Fuentes; Jong-Hun Lee; Ah-Ng Tony Kong
Journal:  Anticancer Agents Med Chem       Date:  2012-12       Impact factor: 2.505

3.  In vitro and in vivo anti-angiogenic activities of Panduratin A.

Authors:  Siew-Li Lai; Shiau-Chuen Cheah; Pooi-Fong Wong; Suzita Mohd Noor; Mohd Rais Mustafa
Journal:  PLoS One       Date:  2012-05-30       Impact factor: 3.240

4.  Pilot study of oral administration of a curcumin-phospholipid formulation for treatment of central serous chorioretinopathy.

Authors:  Fabio Mazzolani
Journal:  Clin Ophthalmol       Date:  2012-05-28

5.  Coral-derived compound WA-25 inhibits angiogenesis by attenuating the VEGF/VEGFR2 signaling pathway.

Authors:  Shih-Wei Lin; Shih-Chung Huang; Hsiao-Mei Kuo; Chiu-Hua Chen; Yi-Ling Ma; Tian-Huei Chu; Youn-Shen Bee; E-Ming Wang; Chang-Yi Wu; Ping-Jyun Sung; Zhi-Hong Wen; Deng-Chyang Wu; Jyh-Horng Sheu; Ming-Hong Tai
Journal:  Mar Drugs       Date:  2015-02-06       Impact factor: 5.118

6.  Discovery of Small Molecules that Target Vascular Endothelial Growth Factor Receptor-2 Signalling Pathway Employing Molecular Modelling Studies.

Authors:  Shailima Rampogu; Ayoung Baek; Chanin Park; Shraddha Parate; Saravanan Parameswaran; Yohan Park; Baji Shaik; Ju Hyun Kim; Seok Ju Park; Keun Woo Lee
Journal:  Cells       Date:  2019-03-21       Impact factor: 6.600

7.  Oral administration of a curcumin-phospholipid delivery system for the treatment of central serous chorioretinopathy: a 12-month follow-up study.

Authors:  Fabio Mazzolani; Stefano Togni
Journal:  Clin Ophthalmol       Date:  2013-05-22

8.  Marine compound catunaregin inhibits angiogenesis through the modulation of phosphorylation of akt and eNOS in vivo and in vitro.

Authors:  Jun-Xiu Liu; Min-Qi Luo; Meng Xia; Qi Wu; Si-Mei Long; Yaohua Hu; Guang-Chun Gao; Xiao-Li Yao; Mian He; Huanxing Su; Xiong-Ming Luo; Shu-Zhong Yao
Journal:  Mar Drugs       Date:  2014-05-12       Impact factor: 5.118

9.  Chloroxylon swietenia (Roxb.) DC induces cell death and apoptosis by down-regulating the NF-κB pathway in MCF-7 breast cancer cells: In vitro and in vivo investigations.

Authors:  Sonali S Kamble; Jasoda Choudhari; Ramakrishna Nimma; Totakura Venkata Santosh Kumar; Kapil K Patil; Shrikant V Hese; Bhaskar S Dawane; Rajesh N Gacche
Journal:  Cancer Rep (Hoboken)       Date:  2022-03-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.